直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Federal Circuit IP Blog

Later Induced Infringement Claims May Not Be Barred by Earlier Direct Infringement Claims

July 13, 2023

Authored and Edited by Matthew R. Ritter; Ryan V. McDonnell; Elizabeth D. Ferrill

In Inguran, LLC V. ABS Global, Inc., No. 22-1385 (Fed. Cir. July 5, 2023), the Federal Circuit reversed a district court’s dismissal of Inguran’s induced infringement claims based on res judicata and it’s ruling on the scope of an ongoing royalty.

In 2014, ABS filed an antitrust lawsuit (“ABS I”) against Inguran, dba STGenetics, (“ST”). ST filed counterclaims alleging direct infringement of U.S. Patent No. 8,206,987 (“the ’987 patent”). ABS stipulated to direct infringement and an ongoing royalty was ordered after trial. The district counter later clarified the royalty order. In 2017, ST filed a second patent infringement lawsuit (“ABS II”), which resulted in another ongoing royalty. In 2020, ST filed yet another patent infringement lawsuit (“ABS III”), alleging induced infringement of the ’987 patent and infringement of two other related patents. ABS moved to dismiss the induced infringement claims, arguing that they were precluded by the district court’s judgment in ABS I. The district court agreed, dismissing the induced infringement claims and holding that the ongoing royalty from ABS I could be reasonably interpreted to cover the third-party conduct identified in ABS III. ST appealed the district court’s determination regarding the finding of claim preclusion and the scope of the ongoing royalty.

On appeal, the Federal Circuit determined that the induced infringement claims in ABS III were not precluded because they were separate causes of action and were not based on the same transactional facts as the direct infringement claims presented in ABS I. In particular, the Court found no support in the record that ST had asserted or cited induced infringement against ABS in ABS I and that the induced-infringement claims centered on the direct infringement of third parties occurring after the ABS I trial. The Court also found that the plain language of the ongoing royalty and clarification in ABS I were limited to direct infringement by ABS and could not reasonably be interpreted to cover actions by third parties in an induced infringement claim.

Related Practices

Appeals, Issues, and Legal Strategy

Federal Circuit and Supreme Court Appeals

Global IP Enforcement, Litigation, and Trials

Antitrust and Misuse

Related Offices

Washington, DC

Contacts

Ryan V. McDonnell
Associate
Washington, DC
+1 202 408 4167
Email
Elizabeth D. Ferrill
Partner
Washington, DC
+1 202 408 4445
Email

Copyright © 2023 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information

Related Insights

Lecture

Munich Licensing Summer Course 2026

June 18-19, 2026

Munich

Articles

Article_D.-Mass-Patent-Litigation-Update-October-2024

D. Mass. Patent Litigation Update: April 2026

June 1, 2026

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

Claim Disclaimer Derails Instituted IPR in Freightcar America

May 26, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP